{
    "clinical_study": {
        "@rank": "122966", 
        "brief_summary": {
            "textblock": "This drug is being developed to treat a type of brain cancer, glioma. This study was\n      designed to determine a safe and well tolerated dose. Patients must have had prior treatment\n      for their glioma and be eligible for removal of their recurring tumor."
        }, 
        "brief_title": "Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.", 
        "completion_date": "August 2003", 
        "condition": [
            "Glioma", 
            "Brain Neoplasm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Neoplasms", 
                "Glioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open label single-dose study to be conducted in 18 evaluable patients with\n      recurrent high-grade glioma. Patient will undergone debulking surgery and ventricular access\n      device placement into the tumor cavity for administration of 131I-TM-601. High-grade glioma\n      includes glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligo-astrocytoma and\n      gliosarcoma.  The amount of 131I will remain constant.  Three doses of TM-601 will be\n      administered using a dose escalating scheme."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patient must have given informed consent\n\n          -  Patient must have histologically confirmed    supratentorial malignant glioma\n\n          -  Patients must have recovered from toxicity of prior therapy\n\n          -  Patients must be eligble for resection of the recurrent tumor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "18", 
        "firstreceived_date": "June 29, 2002", 
        "id_info": {
            "nct_id": "NCT00040573", 
            "org_study_id": "TM601-001"
        }, 
        "intervention": {
            "intervention_name": "131I-TM-601", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Brain neoplasm", 
            "Clinical trial, phase I/II"
        ], 
        "lastchanged_date": "March 30, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-3295"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010-3000"
                    }, 
                    "name": "City of Hope"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110-0250"
                    }, 
                    "name": "Saint Louis University"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Open Label, Single Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients With Recurrent High-Grade Glioma.", 
        "overall_official": {
            "affiliation": "TransMolecular", 
            "last_name": "Diana M Hablitz, MSNCRNP", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040573"
        }, 
        "source": "TransMolecular", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TransMolecular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2009"
    }, 
    "geocoordinates": {
        "City of Hope": "34.139 -117.977", 
        "Saint Louis University": "38.627 -90.199", 
        "University of Alabama at Birmingham": "33.521 -86.802"
    }
}